The domestic sales of sodium-glucose transport protein-2 (SGLT-2) inhibitors in the diabetes treatment market have repeatedly marked rapid growth. The outpatient prescription sales of SGLT-2 inhibitors in Q1 this year increased by 14% from the previous year, continuing its double-digit growth.

The growth is driven by combination therapies. Prescriptions of the two combo therapies ‘Xigduo’ and ‘Jardiance Duo’ have increased by 2.3 times over the past two years.

◆2.3 times increase in prescription of combo drugs… market share also jumps from 27%→39%

According to pharmaceutical market research firm UBIST on the 29th, the SGLT-2 inhibitor class of